Robert W. Baird Has Lowered Expectations for Alto Neuroscience (NYSE:ANRO) Stock Price

Alto Neuroscience (NYSE:ANRO) had its price objective reduced by Robert W. Baird from $41.00 to $38.00 in a research report issued to clients and investors on Thursday,Benzinga reports. The firm presently has an “outperform” rating on the stock. Robert W. Baird’s target price indicates a potential upside of 67.34% from the stock’s previous close.

Several other equities analysts have also recently commented on the stock. Chardan Capital reissued a “buy” rating and set a $30.00 target price on shares of Alto Neuroscience in a research note on Thursday. HC Wainwright reiterated a “buy” rating and set a $50.00 price objective on shares of Alto Neuroscience in a research note on Thursday. Wall Street Zen lowered Alto Neuroscience from a “hold” rating to a “sell” rating in a report on Saturday, March 21st. JonesTrading reduced their price objective on shares of Alto Neuroscience from $49.00 to $44.00 and set a “buy” rating for the company in a report on Thursday. Finally, Jefferies Financial Group restated a “buy” rating and set a $35.00 price target on shares of Alto Neuroscience in a research note on Monday, March 16th. Six investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $35.14.

Alto Neuroscience Stock Down 3.0%

NYSE:ANRO traded down $0.70 during mid-day trading on Thursday, reaching $22.71. The stock had a trading volume of 432,451 shares, compared to its average volume of 251,591. The company has a debt-to-equity ratio of 0.12, a current ratio of 15.69 and a quick ratio of 15.69. The stock’s 50 day simple moving average is $19.09 and its two-hundred day simple moving average is $14.63. Alto Neuroscience has a 1-year low of $1.60 and a 1-year high of $25.17. The company has a market capitalization of $725.43 million, a price-to-earnings ratio of -10.37 and a beta of 2.52.

Alto Neuroscience (NYSE:ANRO) last released its quarterly earnings results on Monday, March 16th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.56) by $0.11. Equities analysts anticipate that Alto Neuroscience will post -2.54 EPS for the current year.

Hedge Funds Weigh In On Alto Neuroscience

Several institutional investors have recently added to or reduced their stakes in ANRO. Invesco Ltd. acquired a new position in Alto Neuroscience in the first quarter valued at about $67,000. AQR Capital Management LLC acquired a new position in shares of Alto Neuroscience in the 1st quarter worth approximately $52,000. Marshall Wace LLP grew its position in Alto Neuroscience by 9.9% during the 2nd quarter. Marshall Wace LLP now owns 937,407 shares of the company’s stock worth $2,062,000 after acquiring an additional 84,417 shares during the last quarter. Armistice Capital LLC grew its position in Alto Neuroscience by 1.5% during the 2nd quarter. Armistice Capital LLC now owns 1,624,000 shares of the company’s stock worth $3,573,000 after acquiring an additional 24,000 shares during the last quarter. Finally, Jane Street Group LLC acquired a new stake in Alto Neuroscience during the 2nd quarter valued at $240,000.

Key Stories Impacting Alto Neuroscience

Here are the key news stories impacting Alto Neuroscience this week:

• Positive Sentiment: HC Wainwright reaffirmed its “buy” rating and set a $50.00 price target, signaling continued bullish conviction from at least one sell‑side shop. Article Title
• Positive Sentiment: JonesTrading kept a “buy” rating despite cutting its price target from $49 to $44, indicating analysts still see meaningful upside to the current price. Article Title
• Positive Sentiment: Chardan Capital reaffirmed a “buy” rating with a $30 price target, providing additional buy‑side support amid near‑term volatility. Article Title
• Neutral Sentiment: Alto announced it is shifting focus toward ALTO‑207 after the ALTO‑101 topline results, which could reallocate resources and change timelines — a strategic pivot that reduces near‑term clarity but may preserve longer‑term pipeline value. Article Title
• Neutral Sentiment: The company’s official press release detailed the topline results and pipeline update; investors will watch follow‑up data, protocol details and management’s development/prioritization plans for valuation impact. Business Wire Release
• Negative Sentiment: Topline Phase 2 results: ALTO‑101 failed to achieve statistical significance on the trial’s primary endpoint — the principal catalyst for the stock decline as it raises questions about the program’s near‑term commercial prospects. Investing.com Article
• Negative Sentiment: Coverage and headlines (e.g., MSN) are highlighting the failed schizophrenia study, increasing negative investor sentiment and trading activity. MSN Article
• Negative Sentiment: Wedbush lowered its price target to $21 (from $22) and moved to a “neutral” rating, reflecting reduced confidence and adding sell‑side pressure. Article Title

Alto Neuroscience Company Profile

Alto Neuroscience (NYSE:ANRO) is a clinical-stage biotechnology company dedicated to advancing precision medicine in neuropsychiatric disorders. The company leverages an integrated digital clinical neuroscience platform that gathers and analyzes multimodal biomarker data—such as electroencephalography (EEG), cognitive assessments and patient-reported outcomes—to predict individual treatment responses. This approach aims to accelerate drug development and improve therapeutic outcomes for conditions like major depressive disorder and treatment-resistant depression.

Alto’s proprietary platform combines data science, machine learning and proprietary algorithms to stratify patient populations and identify responders to investigational therapies.